慢性肾臟病（CKD）市场规模、份额和成长分析（按诊断、治疗方法、给药途径、最终用户和地区划分）—产业预测（2026-2033 年）

全球慢性肾臟病(CKD) 市场规模预计在 2024 年达到 169.3 亿美元，从 2025 年的 203.4 亿美元增长到 2033 年的 880.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 20.1%。

慢性肾臟病（CKD）市场正因糖尿病和高血压盛行率的不断上升而持续增长，而糖尿病和高血压正是CKD的主要诱发因素。全球人口老化进一步加剧了这个问题，因为肾功能会随着老龄化的增长而下降。患者和医疗专业人员对CKD的认识不断提高，促使CKD的早期发现和诊断，最终推动了对治疗药物、干预策略和先进技术治疗方法的需求。这一持续趋势凸显了有效管理方案对于应对日益严重的CKD负担的必要性，并为市场相关人员创造了巨大的机会。随着医疗保健系统不断适应这些挑战，预计市场将继续扩张，这也凸显了治疗方案创新和可近性的重要性。

全球慢性肾臟病市场驱动因素

全球慢性肾臟病市场受到糖尿病和高血压盛行率不断上升的显着影响，这两种疾病是导致肾臟损伤的主要原因。随着患有这些慢性疾病的人群持续增长，对有效治疗方法的需求也将相应增加。糖尿病和高血压发病率的上升将导致慢性肾臟病病患者数量的增加，这将成为推动市场发展的因素。这些慢性疾病与肾臟健康之间的关联凸显了开发先进治疗方法和介入措施以应对和控制这一日益严峻的健康挑战的必要性。

全球慢性肾臟病市场限制因素

全球慢性肾臟病市场面临严峻挑战，其中晚期慢性肾臟病治疗费用高昂是主要原因。透析和肾臟移植等治疗费用昂贵，会给患者带来沉重的经济负担，尤其是在医疗保障有限的地区。这种经济负担不仅阻碍了患者获得所需的治疗，还会影响一个国家医疗体系的整体预算。因此，解决慢性肾臟病治疗中的这些经济难题对于改善患者预后和确保患者公平获得治疗至关重要。

全球慢性肾臟病市场趋势

全球慢性肾臟病市场正呈现出显着的趋势，即早期诊断和积极干预，治疗重点从临终关怀转向预防措施。这种模式转移强调了筛检高风险族群以促进疾病早期发现的重要性。随着医疗保健体系的不断发展，人们对旨在延缓疾病进展、改善患者预后的创新治疗方案的需求日益增长，理想情况下，这些方案应在患者需要透析之前发挥作用。这种积极主动的治疗方法不仅能提升病患的生活质量，还能减轻医疗资源的整体负担，凸显了慢性肾臟病管理领域的变革性观点。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球慢性肾臟病（CKD）市场规模（依诊断分类），复合年增长率（2026-2033 年）

• 血液检查
  • 血清肌酸酐检测
  • 肾丝球过滤率（GFR）测试
  • 血中尿素氮（BUN）检测
  • 电解质测试
• 尿液检查
  • 尿液分析
  • 24小时尿液收集
  • 尿蛋白检测
  • 尿液白蛋白肌酸酐比值（ACR）
• 影像检查
  • 超音波
  • 电脑断层扫描
  • MRI
  • X射线
• 切片检查
  • 经皮皮肾切片检查
  • 开放式切片检查
  • 腹腔镜切片检查

全球慢性肾臟病（CKD）市场规模（依治疗方法划分），复合年增长率（2026-2033 年）

• 药物
• 透析
• 肾臟移植
• ACE抑制剂
• 血液检查
• 其他治疗方法

全球慢性肾臟病（CKD）市场规模（依给药途径划分），复合年增长率（2026-2033 年）

• 口服
• 静脉注射
• 皮下注射

全球慢性肾臟病（CKD）市场规模（按最终用户划分），复合年增长率（2026-2033 年）

• 医院和诊所
• 门诊手术中心（ASC）
• 透析中心
• 其他最终用户

全球慢性肾臟病（CKD）市场规模、复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AstraZeneca（United Kingdom）
• Amgen Inc.（United States）
• Bayer AG（Germany）
• Fresenius Medical Care（Germany）
• DaVita Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Baxter International Inc.（United States）
• Novartis AG（Switzerland）
• Johnson & Johnson（United States）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• AbbVie Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Travere Therapeutics（United States）
• Vera Therapeutics（United States）
• ProKidney（United States）
• Akebia Therapeutics（United States）
• Calliditas Therapeutics AB（Sweden）
• Becton, Dickinson and Company（BD）（United States）
• Renalytix Plc（United Kingdom）

结论与建议

Global Chronic Kidney Disease Market size was valued at USD 16.93 Billion in 2024 and is poised to grow from USD 20.34 Billion in 2025 to USD 88.03 Billion by 2033, growing at a CAGR of 20.1% during the forecast period (2026-2033).

The market for chronic kidney disease (CKD) is experiencing growth due to the increasing prevalence of diabetes and hypertension, which are primary contributors to CKD. The global aging population further exacerbates this issue, as kidney function typically declines with age. Heightened awareness among patients and healthcare professionals regarding CKD leads to earlier detection and diagnosis, ultimately driving demand for therapeutic drugs, intervention strategies, and advanced technological treatments. This ongoing trend underscores the necessity for effective management solutions to address the growing burden of CKD, creating significant opportunities for market players. As healthcare systems adapt to these challenges, the market is poised for continued expansion, emphasizing the importance of innovation and accessibility in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is significantly influenced by the increasing prevalence of diabetes and hypertension, both of which are primary contributors to kidney damage. As the populations affected by these chronic conditions continue to grow, there will be a corresponding rise in the demand for effective treatments. This increasing incidence of both diabetes and high blood pressure will lead to a higher number of individuals diagnosed with chronic kidney disease, thereby driving the market forward. The link between these chronic illnesses and kidney health highlights the necessity for advanced therapies and interventions to manage and address the escalating health challenges.

Restraints in the Global Chronic Kidney Disease Market

The Global Chronic Kidney Disease market faces significant challenges due to the high costs associated with managing advanced stages of the disease. Treatments such as dialysis and kidney transplants entail substantial financial investments, which can create a considerable burden for patients, particularly in regions with limited healthcare coverage. This financial strain not only hinders patient access to necessary care but also impacts the overall budgets of national health systems. Consequently, addressing these economic constraints is crucial for improving patient outcomes and ensuring equitable access to treatment options in the realm of chronic kidney disease management.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant trend towards early diagnosis and proactive intervention, shifting the focus from late-stage treatment to preventive measures. This paradigm shift emphasizes the importance of screening high-risk populations to facilitate timely identification of the disease. As healthcare systems evolve, there is a rising demand for innovative therapeutic solutions designed to slow disease progression and improve patient outcomes, ideally before the need for dialysis arises. This proactive approach not only enhances quality of life for patients but also reduces the overall burden on healthcare resources, highlighting a transformative perspective in chronic kidney disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Test
  • Serum Creatinine Test
  • Glomerular Filtration Rate (GFR) Test
  • Blood Urea Nitrogen (BUN) Test
  • Electrolyte Tests
• Urine Test
  • Urinalysis
  • 24-hour Urine Collection
  • Urine Protein Test
  • Urine Albumin-To-Creatinine Ratio (ACR)
• Imaging Test
  • Ultrasound
  • CT Scan
  • MRI
  • X-ray
• Kidney Biopsy
  • Percutaneous Kidney Biopsy
  • Open Kidney Biopsy
  • Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vera Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProKidney (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renalytix Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations